SEC Tracker
Get the app

Tempest Therapeutics TPST

Tempest Therapeutics appoints John Frederick as director

Item 5.02 Executive or director change, Item 7.01 Investor disclosure

Form
8-K
Filed
Importance
Major
  1. Appointed as Class III director effective October 13, 2026
  2. Received 25,000 shares option under 2023 Equity Incentive Plan
  3. No family relationships or transactions requiring disclosure

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Tempest Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. ProMIS Neurosciences PMN public float $30M, Jun 30, 2025
  2. Provectus Biopharmaceuticals PVCT public float $31M, Jun 30, 2025
  3. Cumberland Pharmaceuticals CPIX public float $29M, Jun 30, 2025
  4. Rockwell Medical RMTI public float $29M, Jun 30, 2025
  5. Champions Oncology CSBR public float $29M, Oct 31, 2025